NCT00567099View on ClinicalTrials.gov

Remediation of Schizophrenia Sensory Gating Deficit With Aripiprazole

NAUnknownINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

August 31, 2003

Study Completion Date

September 30, 2008

Conditions

SchizophreniaSensory Gating

Interventions

DRUG

Aripiprzole

"Dosage form, dosage, frequency and duration:~Aripiprazole 5-30 mg tabs po qday x 3 months"

Trial Locations (1)

87108

RECRUITING

New Mexico VA Healthcare System, Albuquerque

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

New Mexico VA Healthcare System

FED

NCT00567099 - Remediation of Schizophrenia Sensory Gating Deficit With Aripiprazole | Biotech Hunter | Biotech Hunter